Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Has signed written informed consent after the scope and nature of the investigation was explained to them~* Has difficulty falling asleep, maintaining sleep or has early morning awakenings~Exclusion Criteria:~* Significant medical or psychiatric illness causing sleep disturbances~* Has a history of bipolar disorder or family (immediate family) of suicide~* Has sleep disorder such as sleep related breathing disorder, restless leg syndrome, narcolepsy~* Has significant other medical illness such as acute or chronic pain, heart, kidney or liver disease within the last year~* Currently diagnosed or meets the criteria for Major Depressive Disorder (MDD) or has been treated for MDD with the last 2 years~* Substance abuse, excessive use of alcohol (as determined by the physician) or drug addiction within the last year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Esmirtazapine 1.5 mg (Type: EXPERIMENTAL): Esmirtazapine 1.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
- Esmirtazapine 3.0 mg (Type: EXPERIMENTAL): Esmirtazapine 3.0 mg tablet, oral administration in the evening, once daily, for 2 weeks
- Esmirtazapine 4.5 mg (Type: EXPERIMENTAL): Esmirtazapine 4.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to esmirtazapine

Based on this trial design, predict the completion outcome and termination type (if applicable).